DNA methylation of ANKRD23 as a novel biomarker for early diagnosis of ovarian cancer

Basit Öğe Kaydı
dc.authorid0000-0002-5977-1286
dc.authorid0000-0002-0893-1251
dc.authorid0000-0003-4417-4005
dc.authorid0000-0001-6530-0942
dc.authorid0000-0002-5985-070X
dc.authorid0000-0001-6871-8519
dc.authorid0000-0002-8919-0482
dc.authorid0000-0001-8023-3223
dc.contributor.authorAlizada, Aydan
dc.contributor.authorŞükrüoğlu Erdoğan, Özge
dc.contributor.authorKılıç Erciyas, Seda
dc.contributor.authorÇelik Demirbaş, Betül
dc.contributor.authorPasin, Özge
dc.contributor.authorDinç, Ahmet
dc.contributor.authorSaip, Pınar
dc.contributor.authorYazıcı, Hülya
dc.contributor.authorTuncer, Şeref Buğra
dc.date.accessioned2026-08-26T15:34:11Z
dc.date.available2026-08-26T15:34:11Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Tıbbi Biyoloji Ana Bilim Dalı
dc.description.abstractOvarian cancer (OC) is a leading cause of gynecologic cancer-related mortality and is frequently diagnosed at advanced stages due to the absence of effective early detection tools. Epigenetic alterations, particularly DNA methylation, play a critical role in tumorigenesis and represent promising non-invasive biomarkers. This study investigated the methylation status of the ANKRD23 gene in OC and evaluated its diagnostic potential using peripheral blood samples. A total of 385 serous OC patients, 50 individuals with benign ovarian conditions, and 99 healthy controls were included. DNA methylation was assessed using methylation-sensitive restriction enzymes followed by real-time PCR. ANKRD23 methylation was significantly associated with clinical stage (p = 0.029), histological grade (p = 0.009), and ethnicity (p = 0.024). Moreover, methylation levels differed significantly among OC patients, benign cases, and healthy controls (p = 0.026). These findings support blood-based ANKRD23 methylation as a promising biomarker for non-invasive ovarian cancer diagnosis and risk stratification. (Afr J Reprod Health 2026; 30 [15] 16-25).
dc.description.abstractLe cancer de l’ovaire (CO) est l’une des principales causes de mortalité liée aux cancers gynécologiques et est souvent diagnostiqué à des stades avancés en raison de l’absence d’outils efficaces de détection précoce. Les altérations épigénétiques, en particulier la méthylation de l’ADN, jouent un rôle clé dans la tumorigénèse et représentent des biomarqueurs non invasifs prometteurs. Cette étude a évalué le statut de méthylation du gène ANKRD23 dans le cancer de l’ovaire et son potentiel diagnostique à partir d’échantillons de sang périphérique. Au total, 385 patientes atteintes d’un cancer séreux de l’ovaire, 50 individus présentant des pathologies ovariennes bénignes et 99 témoins sains ont été inclus. La méthylation de l’ADN a été analysée à l’aide d’enzymes de restriction sensibles à la méthylation, suivie d’une PCR en temps réel. La méthylation d’ANKRD23 était significativement associée au stade clinique (p = 0,029), au grade histologique (p = 0,009) et à l’origine ethnique (p = 0,024). De plus, les niveaux de méthylation différaient significativement entre les patientes atteintes de cancer de l’ovaire, les cas bénins et les témoins sains (p = 0,026). Ces résultats suggèrent que la méthylation d’ANKRD23 détectée dans le sang constitue un biomarqueur prometteur pour le diagnostic non invasif et la stratification du risque du cancer de l’ovaire. (Afr J Reprod Health 2026; 30 [15]:16-25).
dc.description.sponsorshipThis study was supported by Istanbul University Scientific Research Projects Coordination Unit (Grant No: TYL-2021-38001, TOA-2020-35780). Bu çalışma, İstanbul Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi tarafından desteklenmiştir (Proje No: TYL-2021-38001, TOA-2020-35780).
dc.identifier.citationAlizada, A., Şükrüoğlu Erdoğan, Ö., Kılıç Erciyas, S., Çelik Demirbaş, B., Pasin, Ö., Dinç, A., Saip, P., Yazıcı, H., & Tuncer, Ş. B. (2026). DNA methylation of ANKRD23 as a novel biomarker for early diagnosis of ovarian cancer. African Journal of Reproductive Health, 30(15), pp. 16-25. https://doi.org/10.29063/ajrh2026/v30i15.2
dc.identifier.doi10.29063/ajrh2026/v30i15.2
dc.identifier.endpage25
dc.identifier.issn1118-4841
dc.identifier.issn2141-3606
dc.identifier.issue15
dc.identifier.pmidPMID: 42605682
dc.identifier.scopus2-s2.0-105047545106
dc.identifier.scopusqualityQ3
dc.identifier.startpage16
dc.identifier.urihttps://doi.org/10.29063/ajrh2026/v30i15.2
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1616
dc.identifier.volume30
dc.identifier.wosWOS:001863277400003
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSSCI - Social Science Citation Index
dc.institutionauthorYazıcı, Hülya
dc.institutionauthorid0000-0002-8919-0482
dc.language.isoen
dc.publisherWomen's Health and Action Research Centre
dc.relation.ispartofAfrican Journal of Reproductive Health
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectOvarian Cancer
dc.subjectDNA Methylation
dc.subjectEpigenetic Biomarker
dc.subjectANKRD23 Methylation
dc.subjectCancer de L’ovaire
dc.subjectMéthylation de L’adn
dc.subjectBiomarqueur Épigénétique
dc.subjectMéthylation D’ankrd23
dc.titleDNA methylation of ANKRD23 as a novel biomarker for early diagnosis of ovarian cancer
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text.pdf
Boyut:
620.79 KB
Biçim:
Adobe Portable Document Format
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Temel Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu